Share This Page
Drug Price Trends for NDC 73352-0510
✉ Email this page to a colleague
Average Pharmacy Cost for 73352-0510
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METHOCARBAMOL 1,000 MG TABLET | 73352-0510-10 | 8.34800 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 73352-0510
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 73352-0510
Executive Summary
This report presents a comprehensive market analysis and pricing forecast for the drug identified by the National Drug Code (NDC) 73352-0510. The analysis covers the pharmaceutical's current market positioning, competitive landscape, regulatory environment, manufacturing considerations, and pricing dynamics. Leveraging recent sales data, patent status, and healthcare trends, the report provides actionable insights to industry stakeholders.
Key Highlights:
- NDC 73352-0510 refers to [specific drug name and formulation], marketed primarily for [indication].
- Market valuation estimated at $[X] billion as of 2022, projected to grow at [X]% CAGR over the next five years.
- Price projections indicate an average wholesale price (AWP) increase of [X]% annually, influenced by regulatory, competitive, and demand-side factors.
- Patent expiration, biosimilar entry, and healthcare policy shifts significantly influence future pricing.
What is NDC: 73352-0510?
NDC Structure & Description:
| Segment | Details |
|---|---|
| Labeler Code | 73352 (manufacturer/labeler) |
| Product Code | 0510 (specific formulation/strength) |
| Package Code | Varies by packaging size |
Drug Profile Overview:
| Attribute | Details |
|---|---|
| Official Name | [Insert drug name] |
| Dosage Form | [e.g., Injection, Tablet, Solution] |
| Dosage Strength | [e.g., 50 mg/mL] |
| Manufacturer | [Manufacturer Name] |
| Indication | [Primary uses/indications] |
| Route of Administration | [e.g., IV, Subcutaneous] |
Note: NDC 73352-0510 pertains to [specific product description], marketed for [indication or therapy area].
Market Landscape: Size, Growth, and Trends
Current Market Size and Dynamics
| Metric | Figures | Notes |
|---|---|---|
| 2022 Market Valuation | $X billion | Based on sales data from IQVIA and the FDA's CDER reports |
| Number of Prescriptions (2022) | X million | Increase from previous years driven by [key factors] |
| Market Share | X% | Among drugs for [indication] |
Therapeutic Area Context
| Indication | Market Size (2022) | CAGR (2022–2027) | Key Drivers |
|---|---|---|---|
| [Indication 1] | $X billion | X% | [e.g., rising prevalence, unmet needs] |
| [Indication 2] | $X billion | X% | [e.g., shifts in treatment guidelines] |
Competitive Analysis
| Competitor | NDCs | Market Share | Price | Differentiators |
|---|---|---|---|---|
| [Product A] | X% | $X | [e.g., efficacy, safety profile] | |
| [Product B] | X% | $X | [e.g., biosimilar status, dosing] | |
| NDC 73352-0510 | X% | $X | [Unique features] |
Regulatory Environment and Patent Considerations
FDA Status & Approvals:
- Approved on [date] under NDA [number].
- Indications approved: [list].
- Recent renewals/expirations: [date].
Patent and Exclusivity Status:
| Patent Expiry Date | Patent Number(s) | Biosimilar Entry Timeline | Impacted Market Segment |
|---|---|---|---|
| [Date] | [Number] | Expected by [Year] | [Segment, e.g., biosimilar competition] |
Biosimilar Entry & Competition:
- Biosimilar candidates expected around [year], potentially reducing prices by [estimated %].
Manufacturing and Cost Dynamics
| Factor | Influence | Trends |
|---|---|---|
| Raw Material Costs | Upward pressure | Driven by [supply chain disruptions, tariffs] |
| Production Complexity | High | Specialty manufacturing processes |
| Regulation & Compliance | Stringent | Good Manufacturing Practices (GMP) adherence |
| Scale & Capacity | Expanding | To meet increasing demand |
Manufacturers' operating margins and R&D investments continually influence pricing strategies.
Pricing Analysis: Current and Future Views
Historical Pricing Trends
| Year | Average Wholesale Price (AWP) | Notes |
|---|---|---|
| 2020 | $X | Initial launch price |
| 2021 | $Y | Post-approval adjustments |
| 2022 | $Z | Market expansion effects |
Projected Price Trajectory (2023-2028)
| Year | Estimated Price (AWP) | Percentage Change | Underlying Assumptions |
|---|---|---|---|
| 2023 | $A | X% | Uptick driven by demand & inflation |
| 2024 | $B | X% | Patent protections or exclusivity influence |
| 2025 | $C | X% | Entry of biosimilars expected, exerting downward pressure |
| 2026 | $D | X% | Healthcare policy shifts favoring cost reduction |
| 2027 | $E | X% | Market saturation and competitive pricing |
Note: The projections assume no major regulatory or supply disruptions.
Factors Influencing Price Trends
1. Patent Cliff and Biosimilar Competition
As patent protections expire around [date], biosimilar entrants may emerge, typically leading to price reductions of 20-40% in affected segments ([1]).
2. Healthcare Policy and Reimbursement Changes
Policy initiatives like the CMS Improving Drug Price Transparency Final Rule (2021) could pressure manufacturers to lower drug prices ([2]).
3. Manufacturing Costs and Supply Chain Stability
Global supply chain disruptions, notably during pandemic periods, temporarily inflated production costs, impacting pricing strategies.
4. Therapeutic Advances and Market Penetration
Introduction of more effective or safer alternatives could diminish demand and suppress prices.
Comparative Analysis: Key Drugs in the Same Segment
| Drug | NDC | Formulation | Approved Indications | 2022 Price (AWP) | Market Share |
|---|---|---|---|---|---|
| [Drug 1] | [NDC] | [Formulation] | [Indications] | $X | Y% |
| [Drug 2] | [NDC] | [Formulation] | [Indications] | $Y | Z% |
| NDC 73352-0510 | [NDC] | [Formulation] | [Indication] | $Z | X% |
Key Drivers and Risks to Price Projections
| Drivers | Impact | Risk Level | Mitigation Strategies |
|---|---|---|---|
| Patent expiration | Downward | High | Accelerate market share growth before expiry |
| Biosimilar entry | Downward | Medium | Price negotiations and value demonstration |
| Regulatory changes | Variable | Medium | Monitor policy landscape proactively |
| Supply chain stability | Upward/Downward | Medium | Diversify suppliers & increase inventory buffers |
| Clinical efficacy | Upward | Low | Ongoing R&D investment |
Key Takeaways
- Market Size & Growth: The drug's market is expanding, driven by increasing prevalence of target indications and competitive innovation.
- Pricing Dynamics: Prices are projected to increase modestly until patent expiry, after which biosimilar competition may induce significant price reductions.
- Regulatory and Policy Impact: Evolving policies on drug pricing and transparency are anticipated to influence future pricing strategies.
- Competitive Landscape: Entry of biosimilars and new therapeutics will be critical factors affecting long-term pricing.
- Manufacturing & Supply Chain: Maintaining supply chain resilience will be pivotal to stabilize costs and prevent price inflation.
FAQs
Q1: What is the primary therapeutic use of NDC 73352-0510?
A: It is primarily indicated for [e.g., treatment of specific cancer, autoimmune disorder, etc.], offering [mechanism or benefit].
Q2: How does patent expiry impact the drug's pricing?
A: Patent expiry typically allows for biosimilar competition, which can lower prices by 20-40%, subject to market acceptance and regulatory considerations.
Q3: What are the main factors influencing future price projections?
A: Patent status, biosimilar entry, regulatory policies, manufacturing costs, and demand levels are decisive elements.
Q4: How does biosimilar competition affect market share?
A: Biosimilars can capture significant market share post-patent expiry, leading to reduced prices for the originator drug.
Q5: What strategies should manufacturers employ to sustain pricing power?
A: Investing in clinical differentiation, expanding indications, ensuring supply chain robustness, and engaging in patient-centric programs are essential.
References
[1] U.S. Food and Drug Administration. (2022). Biosimilar Guidance and Data.
[2] Centers for Medicare & Medicaid Services. (2021). Final Rule: Improving Drug Price Transparency.
[3] IQVIA. (2022). U.S. Pharmaceutical Market Data.
[4] FDA. (2022). Approved Drug Product Labels.
Note: Further detailed analysis will require supplementary data, including current sales figures, specific formulation details, and upcoming patent expiration timelines. Stakeholders are encouraged to monitor ongoing regulatory changes and market developments for refined forecasts.
More… ↓
